Pharma BD Deal Intelligence
Lilly pays $3.2 billion to buy Morphic and deepen its immunology and gastroenterology portfolio, though the deal carries inherent Phase 2 risk with…
Eli Lilly acquired Morphic Holdings for $3.19B.
Phase 2 trial of LY4268989 (MORF-057) co-administered with mirikizumab (Omvoh) in moderately-to-severely active ulcerative colitis. Recruiting; started…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Eli Lilly acquired Morphic Holding for $57 per share in cash, approximately $3.19 billion, to gain MORF-057 (later LY4268989), an oral alpha4beta7 integrin inhibitor in Phase 2 development for ulcerative colitis and Crohn's disease positioned as an oral rival to Takeda's injectable IBD franchise. The deal deepened Lilly's immunology and gastroenterology portfolio; Lilly has since advanced the asset into a Phase 2 combination study with its own IL-23 antibody mirikizumab (Omvoh).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Morphic Holdings (this deal) | 2024 | $3.2B | 62 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2024 deals · Eli Lilly and Company deals · Gastroenterology deals